Helius Medical Technologies(US:HSDT)2026-03-30 23:08Revenue Performance - Fourth quarter revenue was $5.2 million, a significant increase from $0.2 million in the prior-year period, primarily driven by $5.1 million in staking rewards[4] - Full year 2025 revenue was $6.0 million, up from $0.5 million in the prior year, reflecting $5.5 million in staking rewards following the launch of the digital asset treasury strategy[11] Operating Expenses - Total operating expenses for the fourth quarter reached $206.1 million, compared to $3.1 million in the prior-year period, including non-cash charges of $178.3 million for unrealized losses on digital assets[7] - Full year operating expenses totaled $249.4 million, compared to $13.8 million in the prior year, with a loss from operations of $243.8 million[13] Net Income - Reported net income for the fourth quarter was $325.6 million, or earnings of $4.25 per share, compared to a net loss of $3.9 million in the prior-year period[10] Capital Raising and Financial Strategy - The company raised $29.9 million in 2025 through ATM programs, primarily used to purchase SOL on a net asset value/share accretive basis[7] - The company initiated a share repurchase program totaling $3.4 million in 2026, funded primarily through the sale of SOL[7] - The company plans to continue pursuing strategic capital markets transactions to achieve its objectives and generate incremental cash flows[3] Digital Asset Management - Cash and digital assets at fair value totaled $301.0 million as of December 31, 2025, with cash at $7.3 million and digital assets valued at $293.7 million[15] - The company launched the first-ever digital asset treasury to enable borrowing against natively staked SOL in qualified custody[7]